Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

ClinicalTrials.gov ID: NCT01491737

Public ClinicalTrials.gov record NCT01491737. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer

Study identification

NCT ID
NCT01491737
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
258 participants

Conditions and interventions

Conditions

Interventions

  • Pertuzumab Drug
  • Trastuzumab Drug
  • Aromatase Inhibitor Drug
  • Induction Chemotherapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 16, 2012
Primary completion
Mar 16, 2016
Completion
Nov 13, 2019
Last update posted
Oct 27, 2020

2012 – 2019

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35249
Ironwood Cancer TX & Rsch Ctrs Chandler Arizona 85224
Genesis Cancer Center Hot Springs Arkansas 71913
Comprehensive Blood & CA Ctr; Research Bakersfield California 93309
Rocky Mountain Cancer Center - Denver Denver Colorado 80220
Norwalk Hospital Norwalk Connecticut 06856
Advanced Medical Specialties Miami Florida 33176
Georgia Cancer Specialists - Northside Atlanta Georgia 30341
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital Marietta Georgia 30060
Cancer Center of Kansas Wichita Kansas 67214-3728
Crescent City Rsrch Cnsrtm, LLC Marrero Louisiana 70072
Weinberg CA Inst Franklin Sq Baltimore Maryland 21237
Center For Cancer and Blood Disorders Bethesda Maryland 20817
Washington University School of Medicine; Internal Medicine - Renal St Louis Missouri 63110
Hematology Oncology Associates; Carol G. Simon Ctr Morristown New Jersey 07960
Cooper Hospital; Hematology & Oncology Voorhees Township New Jersey 08043
NS-Long Island Jewish Hlth Sys Lake Success New York 11042
ProHEALTH Care Associates LLP Lake Success New York 11042
UPMC Cancer Centers Pittsburgh Pennsylvania 15232
Baylor College of Medicine; Lester & Sue Smith Breast Ctr Houston Texas 77030
Scott and White Hospital; Cancer Center Temple Texas 76508

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01491737, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01491737 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →